On July 6, Novartis announced that it has reached an agreement to acquire British biotech company Myricx Bio for up to $1.5 billion, with an upfront payment of $1.1 billion, plus potential milestone payments of up to $400 million. The transaction is expected to close in the second half of 2026, pending regulatory approval.